Skip to main content
Top
Published in: Annals of Surgical Oncology 11/2018

01-10-2018 | Endocrine Tumors

Differences in the Impact of Age on Mortality in Well-Differentiated Thyroid Cancer

Authors: Huan Yan, MD, David J. Winchester, MD, Richard A. Prinz, MD, Chi-Hsiung Wang, PhD, Yoko Nakazato, MD, Tricia A. Moo-Young, MD

Published in: Annals of Surgical Oncology | Issue 11/2018

Login to get access

Abstract

Introduction

Well-differentiated thyroid cancer (WDTC) is unique in that patient age is part of staging. Several studies have shown a need to increase the age threshold in staging for WDTC, but the separate impact of age on prognosis for papillary and follicular carcinomas has not been examined. We hypothesize that age impacts survival differently for papillary and follicular carcinomas.

Methods

Patients with invasive papillary thyroid carcinoma (PTC) and follicular thyroid carcinoma (FTC) between 2004 and 2013 were identified in the National Cancer Database, and were stratified by histologic type. Overall survival (OS) was analyzed using multivariable Cox regression, and the Youden index was used to find the optimal age threshold for both histologies.

Results

A total of 204,139 patients with WDTC were identified. Ninety-two percent had PTC, while 7.7% had FTC. The average age was 48.4 years and OS was 96.3%, with a median follow-up of 52.7 months. When analyzing age in 5-year increments, 10-year mortality increased incrementally by 30–50% per age group for PTC, from age < 35 to ≥ 70 years, without an obvious inflection point. However, FTC patients experienced a more than threefold increase in 10-year mortality from age 40–44 years (2.5%) to age 45–49 years (7.9%). The same pattern was found on multivariable Cox regression. The Youden index found the optimal age thresholds were 58.5 years for PTC and 46.2 years for FTC.

Conclusion

OS for PTC decreases incrementally with age, but OS for FTC decreases significantly in patients aged 45 years and older. A higher age threshold may inappropriately downstage some high-risk follicular cancer patients.
Literature
1.
go back to reference Haymart MR. Understanding the relationship between age and thyroid cancer. Oncologist. 2009;14(3):216–21.CrossRef Haymart MR. Understanding the relationship between age and thyroid cancer. Oncologist. 2009;14(3):216–21.CrossRef
2.
go back to reference Ganly I, Nixon IJ, Wang LY, Palmer FL, Migliacci JC, Aniss A, et al. Survival from differentiated thyroid cancer: what has age got to do with it? Thyroid. 2015;25(10):1106–14.CrossRef Ganly I, Nixon IJ, Wang LY, Palmer FL, Migliacci JC, Aniss A, et al. Survival from differentiated thyroid cancer: what has age got to do with it? Thyroid. 2015;25(10):1106–14.CrossRef
3.
go back to reference Hendrickson-Rebizant J, Sigvaldason H, Nason RW, Pathak KA. Identifying the most appropriate age threshold for TNM stage grouping of well-differentiated thyroid cancer. Eur J Surg Oncol. 2015;41(8):1028–32.CrossRef Hendrickson-Rebizant J, Sigvaldason H, Nason RW, Pathak KA. Identifying the most appropriate age threshold for TNM stage grouping of well-differentiated thyroid cancer. Eur J Surg Oncol. 2015;41(8):1028–32.CrossRef
4.
go back to reference Kim S, Myong JP, Suh H, Lee KE, Youn Y-K. Optimal cutoff age for predicting mortality associated with differentiated thyroid cancer. Soares P, ed. PLoS One. 2015;10(6):e0130848.CrossRef Kim S, Myong JP, Suh H, Lee KE, Youn Y-K. Optimal cutoff age for predicting mortality associated with differentiated thyroid cancer. Soares P, ed. PLoS One. 2015;10(6):e0130848.CrossRef
5.
go back to reference Nixon IJ, Wang LY, Migliacci JC, Eskander A, Campbell MJ, Aniss A, et al. An international multi-institutional validation of age 55 years as a cutoff for risk stratification in the AJCC/UICC staging system for well-differentiated thyroid cancer. Thyroid. 2016;26(3):373–80.CrossRef Nixon IJ, Wang LY, Migliacci JC, Eskander A, Campbell MJ, Aniss A, et al. An international multi-institutional validation of age 55 years as a cutoff for risk stratification in the AJCC/UICC staging system for well-differentiated thyroid cancer. Thyroid. 2016;26(3):373–80.CrossRef
6.
go back to reference Kim M, Kim WG, Oh HS, Park S, Kwon H, Song DE, et al. Comparison of the Seventh and Eighth Editions of the American Joint Committee on Cancer/Union for International Cancer Control Tumor-Node-Metastasis Staging System for Differentiated Thyroid Cancer. Thyroid. 2017;27(9):1149–1155.CrossRef Kim M, Kim WG, Oh HS, Park S, Kwon H, Song DE, et al. Comparison of the Seventh and Eighth Editions of the American Joint Committee on Cancer/Union for International Cancer Control Tumor-Node-Metastasis Staging System for Differentiated Thyroid Cancer. Thyroid. 2017;27(9):1149–1155.CrossRef
7.
go back to reference Machens A, Holzhausen HJ, Dralle H. The prognostic value of primary tumor size in papillary and follicular thyroid carcinoma. Cancer. 2005;103(11):2269–73.CrossRef Machens A, Holzhausen HJ, Dralle H. The prognostic value of primary tumor size in papillary and follicular thyroid carcinoma. Cancer. 2005;103(11):2269–73.CrossRef
8.
go back to reference Aboelnaga EM, Ahmed RA. Difference between papillary and follicular thyroid carcinoma outcomes: an experience from Egyptian institution. Cancer Biol Med. 2015;12(1):53–9.PubMedPubMedCentral Aboelnaga EM, Ahmed RA. Difference between papillary and follicular thyroid carcinoma outcomes: an experience from Egyptian institution. Cancer Biol Med. 2015;12(1):53–9.PubMedPubMedCentral
9.
go back to reference Sugino K, Kameyama K, Nagahama M, Kitagawa W, Shibuya H, Ohkuwa, K, et al. Prognosis of follicular thyroid carcinoma. 内分泌甲状腺外会志 2013;30 (1):7–12. Sugino K, Kameyama K, Nagahama M, Kitagawa W, Shibuya H, Ohkuwa, K, et al. Prognosis of follicular thyroid carcinoma. 内分泌甲状腺外会志 2013;30 (1):7–12.
10.
go back to reference Ito Y, Hirokawa M, Masuoka H, Yabuta T, Kihara M, Higashiyama T, et al. Prognostic factors of minimally invasive follicular thyroid carcinoma: extensive vascular invasion significantly affects patient prognosis. Endocr J. 2013;60(5):637–42.CrossRef Ito Y, Hirokawa M, Masuoka H, Yabuta T, Kihara M, Higashiyama T, et al. Prognostic factors of minimally invasive follicular thyroid carcinoma: extensive vascular invasion significantly affects patient prognosis. Endocr J. 2013;60(5):637–42.CrossRef
11.
go back to reference Adam MA, Thomas S, Hyslop T, Scheri RP, Roman SA, Sosa JA Exploring the relationship between patient age and cancer-specific survival in papillary thyroid cancer: rethinking current staging systems. J Clin Oncol. 2016;34(36):4415–4420.CrossRef Adam MA, Thomas S, Hyslop T, Scheri RP, Roman SA, Sosa JA Exploring the relationship between patient age and cancer-specific survival in papillary thyroid cancer: rethinking current staging systems. J Clin Oncol. 2016;34(36):4415–4420.CrossRef
12.
13.
go back to reference Ito Y, Fukushima M, Yabuta T, Tomoda C, Inoue H, Kihara M, et al. Local prognosis of patients with papillary thyroid carcinoma who were intra-operatively diagnosed as having minimal invasion of the trachea: a 17-year experience in a single institute. Asian J Surg. 2009;32(2):102–8.CrossRef Ito Y, Fukushima M, Yabuta T, Tomoda C, Inoue H, Kihara M, et al. Local prognosis of patients with papillary thyroid carcinoma who were intra-operatively diagnosed as having minimal invasion of the trachea: a 17-year experience in a single institute. Asian J Surg. 2009;32(2):102–8.CrossRef
14.
go back to reference Black WC, Haggstrom DA, Welch HG. All-cause mortality in randomized trials of cancer screening. J Natl Cancer Inst. 2002;94(3):167–73.CrossRef Black WC, Haggstrom DA, Welch HG. All-cause mortality in randomized trials of cancer screening. J Natl Cancer Inst. 2002;94(3):167–73.CrossRef
Metadata
Title
Differences in the Impact of Age on Mortality in Well-Differentiated Thyroid Cancer
Authors
Huan Yan, MD
David J. Winchester, MD
Richard A. Prinz, MD
Chi-Hsiung Wang, PhD
Yoko Nakazato, MD
Tricia A. Moo-Young, MD
Publication date
01-10-2018
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 11/2018
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-018-6668-2

Other articles of this Issue 11/2018

Annals of Surgical Oncology 11/2018 Go to the issue